Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues

Pathobiology

Volumn 78, Issue 1, 2011, Pages 1-9

  Arai, Eri ^a   Wakai Ushijima, Saori ^a   Fujimoto, Hiroyuki ^c   Hosoda, Fumie ^b   Shibata, Tatsuhiro ^b   Kondo, Tadashi ^a   Yokoi, Sana ^d   Imoto, Issei ^d   Inazawa, Johji ^d   Hirohashi, Setsuo ^a   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b Cancer Genomics Project   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chromophobe renal cell carcinoma; Clear cell renal cell carcinoma; DNA methylation; Oncocytoma; Papillary renal cell carcinoma; Precancerous condition

Indexed keywords

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CLASSIFICATION; CHROMOPHOBE ADENOMA; CLINICAL ARTICLE; CPG ISLAND; DNA METHYLATION; GENE AMPLIFICATION; GENE CLUSTER; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; ONCOCYTOMA; PRIORITY JOURNAL;

ADENOMA, OXYPHILIC; CARCINOMA, RENAL CELL; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; TISSUE ARRAY ANALYSIS;

BACTERIA (MICROORGANISMS);

EID: 79953871529     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322072     Document Type: Article

References (32)

1. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428. (Pubitemid 34587077)
2. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455. (Pubitemid 36444319)
3. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116. (Pubitemid 43361543)
4. Kanai Y, Hirohashi S: Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007; 28: 2434-2442. (Pubitemid 350238944)
5. Kanai Y: Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int 2008; 58: 544-558.
6. Eble JN, Togashi K, Pisani P: Renal cell carcinoma; in Eble JN, Sauter G, Epsterin JI (ed): World Health Organzation Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2008, pp 10-43.
7. Arai E, Ushijima S, Tsuda H, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genetic clustering of clear cell renal cell carcinoma based on array-CGH: its association with DNA methylation alteration and patient outcome. Clin Cancer Res 2008; 14: 5531-5539.
8. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S: Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006; 119: 288-296.
9. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 2009; 30: 214-221.
10. Arai E, Kanai Y: DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics 2010; 2: 476-481.
11. Kanai Y: Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010; 101: 36-45.
12. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE, Cairns P: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003; 63: 8695-8699. (Pubitemid 38064046)
13. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al- Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grezle WE, Cairns P: Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004; 10: 3972-3979. (Pubitemid 38812470)
14. Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F, Ohki M, Imoto I, Inazawa J: Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res 2005; 65: 10233-10242. (Pubitemid 41743715)
15. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T, Imoto I, Inazawa J: Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene 2007; 26: 7401-7413. (Pubitemid 350158713)
16. Tanaka K, Imoto I, Inoue J, Kozaki K, Tsuda H, Shimada Y, Aiko S, Yoshizumi Y, Iwai T, Kawano T, Inazawa J: Frequent methylationassociated silencing of a candidate tumorsuppressor, CRABP1, in esophageal squamous- cell carcinoma. Oncogene 2007; 26: 6456-6468. (Pubitemid 47494215)
17. Inazawa J, Inoue J, Imoto I: Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-563. (Pubitemid 39089635)
18. Illingworth R, Kerr A, Desousa D, Jorgensen H, Jorgensen H, Ellis P, Stalker J, Jackson D, Clee C, Plumb R, Rogers J, Humphray S, Cox T, Langford C, Bird A: A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol 2008; 6: 22.
19. Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 2009; 125: 2854-2862.
20. Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, Kondo T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci 2010; 101: 231-240.
21. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N, Dahiya R: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 2004; 316: 1156-1162. (Pubitemid 38369074)
22. Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K, Yasui W: DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 2003; 94: 901-905. (Pubitemid 37406973)
23. Estecio MR, Yan PS, Ibrahim AE, Tellez CS, Shen L, Huang TH, Issa JP: High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007; 17: 1529-1536. (Pubitemid 47529437)
24. Jacinto FV, Ballestar E, Ropero S, Esteller M: Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 2007; 67: 11481-11486.
25. Nielander I, Bug S, Richter J, Giefing M, Martin-Subero JI, Siebert R: Combining array- based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. APMIS 2007; 115: 1107-1134. (Pubitemid 350179480)
26. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T: High levels of aberrant DNA methylation in Helicobacter pylori- infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006; 12: 989-995. (Pubitemid 43259882)
27. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ: Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006; 38: 540-549.
28. Waldert M, Haitel A, Marberger M, Katzenbeisser D, Ozsoy M, Stadler E, Remzi M: Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int 2008; 102: 1381-1384.
29. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS: Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res 2009; 15: 1162-1169.
30. Adley BP, Smith ND, Nayar R, Yang XJ: Birt- Hogg-Dubé syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 2006; 130: 1865-1870. (Pubitemid 44906968)
31. Monzon FA, Hagenkord JM, Lyons-Weiler MA, Balani JP, Parwani AV, Sciulli CM, Chandran UR, Bastacky SI, Dhir R: Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 2008; 21: 599-608. (Pubitemid 351589654)
32. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27: 612-624. (Pubitemid 36514472)